Tisagenlecleucel

Outcomes of children and young adults with B-ALL following tisa-cel reinfusion 3:52
Outcomes of children and young adults with B-ALL following tisa-cel reinfusion
Kevin McNerney • 24 Feb 2023
Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy 5:36
Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy
Veit Buecklein • 9 Dec 2022
Engineering NK cell-based cancer treatments 1:22
Engineering NK cell-based cancer treatments
Juliane Mietz • 1 Apr 2022
Accelerating commercialization in advanced therapies 3:08
Accelerating commercialization in advanced therapies
Pascal Touchon • 7 Apr 2021
An overview of the CAR T-cell therapy story 3:39
An overview of the CAR T-cell therapy story
Mohamad Mohty • 26 Jan 2021
Practical aspects of CAR T-cell therapy 4:14
Practical aspects of CAR T-cell therapy
Ulrich Jäger • 9 Feb 2021
The challenges of CAR T-cell therapy for pediatric B-ALL 4:18
The challenges of CAR T-cell therapy for pediatric B-ALL
Sara Ghorashian • 4 Feb 2021
Updates on CAR T-cell therapy in B-cell malignancies 2:16
Updates on CAR T-cell therapy in B-cell malignancies
Ulrich Jäger • 9 Feb 2021
CAR-T therapy for aggressive B-cell lymphomas 2:42
CAR-T therapy for aggressive B-cell lymphomas
Peter A. Riedell • 2 Sep 2020
Anti-CD19 CAR T-cells for adults 4:51
Anti-CD19 CAR T-cells for adults
David L. Porter • 9 Sep 2020
Real-world efficacy & safety data: CAR-T in DLBCL 3:05
Real-world efficacy & safety data: CAR-T in DLBCL
Matthew Frigault • 1 Sep 2020
Tocilizumab: CAR T-cell therapy in DLBCL 2:18
Tocilizumab: CAR T-cell therapy in DLBCL
Matthew Frigault • 1 Sep 2020
The content of VJRegenMed is intended for healthcare professionals